Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction

Core Insights - Hedge fund BVF disclosed a new position in Disc Medicine, acquiring 650,000 shares valued at $51.62 million as of February 17, 2026 [2][10] - Disc Medicine, Inc. is a clinical-stage biotechnology company focused on developing therapies for rare blood diseases, leveraging expertise in red blood cell biology [6][9] Company Overview - Market capitalization of Disc Medicine is $2.48 billion [4] - The share price as of February 17, 2026, was $65.57, reflecting a one-year price change of 20.03% [4][8] - The company reported a net income of -$181.11 million (TTM) [4] Investment Implications - Disc Medicine represents approximately 1.74% of BVF's 13F reportable assets under management (AUM) after the acquisition [8] - The investment was made prior to the FDA's Complete Response Letter and subsequent market selloff, indicating a focus on the company's scientific fundamentals rather than short-term trading [10] - The company ended 2025 with approximately $791 million in cash and marketable securities, providing a financial runway into 2029 [11] Clinical Development - Disc Medicine is developing therapeutics targeting heme biosynthesis and iron homeostasis for serious hematologic diseases [9] - The FDA has acknowledged the efficacy of bitopertin in lowering PPIX in EPP patients but requires further data to establish clinical outcomes, with ongoing Phase 3 APOLLO trial results expected in Q4 [11] - The investment thesis for Disc Medicine is now heavily reliant on the outcomes of the APOLLO trial and the company's capital durability [12]